US Food and Drug Administration Commissioner Marty Makary said he’s trying to persuade Vinay Prasad, the agency’s former head ...

Oral, non-opioid drug candidate advancing through Phase 1 and nearing completion of the single ascending dose (SAD) portion ...

Correspondence from the Ashanti Region Following a recent sensitization program at the Santasi Market as part of the World Food Safety Day, John Laryea Odai-Tettey, Ashanti Region ...

Tidmarsh will temporarily guide CBER’s regulatory activities while the FDA searches for a permanent department lead.

George Tidmarsh is taking on more responsibilities at FDA after the sudden departure of top official Vinay Prasad.

Vinay Prasad has stepped down as head of the FDA's Center for Biologics Evaluation and Research (CBER), less than three ...

The SPDR® S&P Biotech ETF rebounded over 20% since lows in April, despite changes at the FDA that could have signaled a ...

Vinay Prasad, head of the Center for Biologics Evaluation and Research (CBER) at the US Food and Drug Administration (FDA), ...

Just a few weeks before the start of the 2025 NFL season, the NFL has issued a pretty significant ban on one particular ...

George Tidmarsh has only been at the Center for Drug Evaluation and Research for nine days, but will now add supervision of a ...

Sarepta (NASDAQ:SRPT) stock, Replimune (NASDAQ:REPL) stock and Capricor (CAPR) stock surge as FDA's biologics head exits abruptly. Read more here.

The NFL is banning the use of smelling salts during games, citing safety concerns and the potential to mask concussion ...